Is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a buy, sell, or hold? Money managers are in a pessimistic mood. The number of long hedge fund bets retreated by 2 lately.
To most traders, hedge funds are seen as unimportant, outdated investment tools of the past. While there are greater than 8000 funds in operation at present, we hone in on the crème de la crème of this club, close to 450 funds. It is widely believed that this group oversees the lion’s share of all hedge funds’ total capital, and by monitoring their best equity investments, we have brought to light a few investment strategies that have historically outperformed the S&P 500 index. Our small-cap hedge fund strategy outstripped the S&P 500 index by 18 percentage points per annum for a decade in our back tests, and since we’ve started sharing our picks with our subscribers at the end of August 2012, we have trumped the S&P 500 index by 23.3 percentage points in 8 months (explore the details and some picks here).
Equally as beneficial, positive insider trading sentiment is a second way to break down the investments you’re interested in. There are many motivations for an executive to cut shares of his or her company, but just one, very clear reason why they would buy. Several academic studies have demonstrated the impressive potential of this tactic if piggybackers understand where to look (learn more here).
Consequently, let’s take a gander at the key action surrounding ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).
Hedge fund activity in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
At Q1’s end, a total of 10 of the hedge funds we track were bullish in this stock, a change of -17% from the previous quarter. With hedge funds’ sentiment swirling, there exists a select group of key hedge fund managers who were boosting their holdings significantly.
According to our comprehensive database, Julian Baker and Felix Baker’s Baker Bros. Advisors had the biggest position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), worth close to $124 million, comprising 2.5% of its total 13F portfolio. Coming in second is Peter Kolchinsky of RA Capital Management, with a $62.2 million position; the fund has 13.3% of its 13F portfolio invested in the stock. Remaining hedge funds with similar optimism include Jacob Gottlieb’s Visium Asset Management, and Samuel Isaly’s OrbiMed Advisors.
Judging by the fact that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has faced declining sentiment from the aggregate hedge fund industry, we can see that there exists a select few money managers who were dropping their entire stakes heading into Q2. It’s worth mentioning that Joseph Edelman’s Perceptive Advisors dumped the biggest position of all the hedgies we watch, comprising about $1.9 million in stock.. Glenn Russell Dubin’s fund, Highbridge Capital Management, also cut its stock, about $0.1 million worth. These transactions are important to note, as aggregate hedge fund interest was cut by 2 funds heading into Q2.
How have insiders been trading ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?
Bullish insider trading is best served when the primary stock in question has experienced transactions within the past 180 days. Over the last 180-day time frame, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has experienced 1 unique insiders purchasing, and 4 insider sales (see the details of insider trades here).
Let’s also take a look at hedge fund and insider activity in other stocks similar to ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). These stocks are Array Biopharma Inc (NASDAQ:ARRY), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Halozyme Therapeutics, Inc. (NASDAQ:HALO), and EXACT Sciences Corporation (NASDAQ:EXAS). This group of stocks are in the biotechnology industry and their market caps are closest to ACAD’s market cap.
